Powerpoint presentation


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • SEB has an attractive platform * 50% of the results is generated outside Sweden The Baltic countries accounts for 14 percent of the result Strong position within Merchant Banking, Asset Management and Private Banking – all areas with extensive advisory services. Trygg-Liv market leading Swedish position in Unit linked More than 50% of our employees are located outside Sweden The other nordic countries accounts for 20 percent of the result Ranking results – voluntary to choose from: Best bank at cash management in the Nordic region (Euromoney, TMI) Best bank at cash management in the Baltic region (Euromoney) Best asset manager in Sweden (Prospera) Best corporate finance house in Sweden, Finland, Norway, Denmark (Prospera) Best mutual fund company in Europe (no 2) (Prospera) Best bank in Latvia (Euromoney) Best bank in Lithuania (Euromoney) Best private bank in Sweden (Euromoney) Best Commercial bank of the year (2) (Swedish business magazine Affärsvärlden) Best credit card issuer in the Nordic region (Cards International) Best life insurance company in Sweden (The Swedish insurance broker association)
  • 3 IPOs 1 liquid 4 home runs (Dynasoft, Epigress, Bluetail, Pyrosequencing)
  • Total Sales 2002 - SEKM 1,400 +60% (over 2001) Total loss SEKM 470 -38% (SEKM -770 in 2001) 1100 people employed Figures does not incl Mamma Mia! With some SEKM 2,000 in sales in 2002
  • Powerpoint presentation

    1. 1. SEB Företagsinvest - an active Venture Capital partner
    2. 2. A north european financial group <ul><li>History </li></ul><ul><li>Established player - SEB founded in 1856 </li></ul><ul><li>Wallenberg family have a significant shareholding </li></ul><ul><li>Significant Resources </li></ul><ul><li>Listed on Stockholm Stock Exchange with a </li></ul><ul><li>market capitalization of €13.2 billion </li></ul><ul><li>Total Assets in excess of €210 billion </li></ul><ul><li>€ 115 billion in Asset under Management </li></ul><ul><li>Total Book Equity in excess of €6.4 billion </li></ul><ul><li>Global presence </li></ul><ul><li>Local presence in ten countries + strategic locations globally </li></ul><ul><li>Over 20.000 employees </li></ul>
    3. 3. SEB Group offers a full range of financial services Group Staff Hans Larsson/Per-Arne Blomquist Group IT Max Currie Group Operations Pia Warnerman Internal Audit Agneta Brevenhag Group Credits & Group Risk Control Johan Andersson President & CEO Annika Falkengren Merchant Banking Magnus Carlsson Retail Banking Bo Magnusson Life Anders Mossberg Wealth Management Fredrik Boheman
    4. 4. Enskilda Securities SEB Acquisition Finance EUR 1.5bn SEB Företagsinvest - EURM 130 SEB Strategic Investment – EURM 100 SEB Private Equity – EUR 1.1bn SEB is a significant player in the private equity market KTH Seed Capital In addition, SEB is an investor in EQT, Innovations Kapital, AskEmbla (Baltics) etc Bank financing Venture Capital Seed Capital Start-up Expansion Buy-out IPO M&A Company life cycle
    5. 5. SEB Företagsinvest - one of Sweden’s leading venture capital investors <ul><li>Our business concept… </li></ul><ul><li>We invest venture capital and supply expertise </li></ul><ul><li>and a broad network of contacts to growth </li></ul><ul><li>companies in the Technology and Life Science sectors </li></ul>
    6. 6. SEB Företagsinvest in brief… <ul><li>Evergreen fund structure SEK 1,200m </li></ul><ul><li>No. of existing investments 40 </li></ul><ul><li>No. of exits 35 </li></ul><ul><li>No. of investment professionals 14 </li></ul><ul><li>Established 1995 </li></ul>
    7. 7. <ul><li>Balanced portfolio vis-à-vis sector and maturity </li></ul><ul><li>Minority owners </li></ul><ul><li>Max. investment sum SEK 80m </li></ul><ul><li>Investment horizon of up to 7 years </li></ul><ul><li>Exits </li></ul>SEB Företagsinvest in brief...
    8. 8. Investment criteria <ul><li>The company has a unique product or service with a sustainable competitive edge </li></ul><ul><li>Highly skilled management who are also partners in the company </li></ul><ul><li>Business concept with international market potential </li></ul>
    9. 9. Active ownership - value creation <ul><li>Powerful networks </li></ul><ul><li>Experienced venture team </li></ul><ul><li>Industry-specific expertise </li></ul><ul><li>Close co-operation with management </li></ul><ul><li>Commitment </li></ul><ul><li>Board representation </li></ul>
    10. 10. Professionals Frederick Johansson Head of unit Arpinée Åhrberg Assistant Hans Engblom Björn Österlund O la Romney Senior Investment Managers Jonas Nyman Rickard Malmsjö Investment Managers Patrik Westerberg Stefan Olofsson Anna Gustafsson Ulf Lewander Anna Ljungdahl Business Controller Andreas Pennervall Business Development Technology David Sonnek, PhD Business Development Health Care Viktor Drvota, MD, PhD Malin Carlström Venture Analyst
    11. 11. Portfolio - key figures 1996-97 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Portfolio, no of companies 9 8 15 27 35 37 38 39 40 38 40 Exits, no of companies 1 3 8 10 15 19 21 26 29 35 35 Cumulative paid out capital 50 70 220 360 580 755 910 1100 1220 1380 1450 No. of employees 3 4 7 11 12 13 13 14 14 16 16
    12. 12. Co- investors 3i ABN Amro Abingworth Applied Biosystems Alafi Capital Atlas Ventures Bankinvest Beijer Biofund Bure CapMan Centrecourt Chalmersinvest Cimon Cirkus Concordia Capital CR&T Credit Suisse Dansk Kapitalanlaeg Danish Investment Fund EMA Emano Företagsbyggarna GE Capital Healthcap H&B Capital IDI Industrifonden Industrivärden Innovationskapital Investor Growth Capital Kantonal Bank Karolinska Investment Fund KIHAB Latour Malmöhusinvest Metall Metallica Microdrug Nordic BioScience Nordic Biotech Novo AS Optiomi Pomona Schibstedt 6:e AP-Fonden SLS Skandia Skanditek Universal W-Capital Wallgrund Öresund
    13. 13. 35 Exits to date Divestment of to Biovitrum AB Amount not disclosed 2005 Divestment of to Motorola Inc Amount not disclosed 2006 Divestment of to Wind River For a value of $21.5m 2006 Divestment of to Crucell N.V. for a min value of EUR 39,4m 2006 Divestment of to Aixtron AG amount not disclosed 1998 Initial Public Offering of on the Stockholm SE for a value of SEKM 2,500 2000 Divestment of to Nortel for a total of SEKM 1,400 2000 The number 1 selling show world wide Grand opening 1999 Divestment of to Segulah and founders amount not disclosed 2004 Divestment of to Astra Tech Amount not disclosed 2005 Divestment of to a consortium of private investors Amount not disclosed 2004
    14. 14. Investment focus Growth companies within... Life Science Technology Life Science Technology
    15. 15. Emers Holding SANOS BIOSCIENCE
    16. 16. Portfolio companies - Technology <ul><li>A system for the manufacture of powerful, compact lasers in visible and infra-red wavelengths </li></ul><ul><li>Develops and administers loyalty schemes within CRM </li></ul><ul><li>Platforms and products in telematics, e.g. elevator communication </li></ul><ul><li>Software applications for technical decision support, based on v isualised web technology </li></ul>
    17. 17. Portfolio companies - Technology <ul><li>Software program for long-term planning and scheduling of personnel </li></ul><ul><li>Software solution for diagnostics and maintenance of complex and mission critical software control systems. </li></ul><ul><li>ABBA musical in London, Toronto, USA and Australia etc. 16 shows globally </li></ul><ul><li>Software/consulting firm that provides activity-based and process-oriented management solutions </li></ul>
    18. 18. Portfolio companies - Technology <ul><li>CAPRES develops new technology for direct nano- and micro- scale electrical characterization of materials. </li></ul><ul><li>Develop and sell products, based on centrifugal separation, for purification of process air to several industrial applications. </li></ul><ul><li>Develops and sells a software platform to telecom operators to help in their process of trading, pricing and routing international interconnect voice traffic. </li></ul><ul><li>KTH Seed Capital invests in early stage high-tech companies relating Research and Development at Royal Institute of Technology (KTH). </li></ul>
    19. 19. Portfolio companies - Technology <ul><li>ScandiNova develops and sells solid state modulators (high power pulse generators) for applications such as radar systems, lasers, radiotherapy systems, research accelerators and X-ray systems. </li></ul><ul><li>Matrix is a supplier of architectural services in visualization and 3D modeling. Matrix offers attractively packaged solutions to industries such as real estate and whitegoods. </li></ul><ul><li>Tail-f develops On-Device Management Software solutions for network equipment vendors, reducing development costs and speed time-to-market. </li></ul><ul><li>SP Devices develops and markets signal processing electronics and algorithms. </li></ul>
    20. 20. Portfolio companies - Life Science <ul><li>Technology for fetal monitoring during the final stage of delivery with focus on oxygen supply to the brain. </li></ul><ul><li>Digital X-ray imaging based on photon counting </li></ul><ul><li>Products for minimally invasive treatment of enlarged prostate </li></ul><ul><li>Biotage AB is a leading supplier of complete solutions for Medical Chemistry Research and Applied genomic Analysis </li></ul><ul><li>EMERS Holding is the holding company of Bactus AB and LightUp Technologies AB. LightUp markets PNA based probes for the diagnostic market within human infectious diseases. Bactus is a company dedicated to clinical and industrial microbiology with production of substrates for various applications. </li></ul>Emers Holding
    21. 21. Portfolio companies – Life Science <ul><li>Develops extremely compact multi-parameter probes. The target group for these is international medical equipment companies working within the field of anesthesia, intensive care and emergency care. </li></ul><ul><li>Medical supplier of fertility systems, transplantation systems and biosupportive systems </li></ul><ul><li>Sanos Bioscience is a drug discovery company which develops new compounds for its new proprietary glucagon-like peptide-2 (GLP-2) pathway for the treatment and prevention of osteoporosis. The company will focus on clinical studies aiming to confirm the promising results from pilot studies. </li></ul>SANOS BIOSCIENCE
    22. 22. Portfolio companies – Life Science <ul><li>Discover and develops so called DIMS drugs (DIMS: DNA-based Immunomodulary Sequence) for unmet medical needs in a variety of treatment areas such as inflammation and cancer. DIMS compounds contain oligonucleotides, which intreract with Toll-like Receptors (TLR). </li></ul><ul><li>Oligovation is a research-based company developing innovative tools for genetic analysis, molecular diagnostics, and gene-based therapeutics. </li></ul><ul><li>Nuevolution is a drug discovery company poised to revolutionize drug discovery and development by utilising its proprietary Chemetics ® technologies ( molecular evolution) to rapidly identify vast amounts of drug-like, high affinity selective small molecules for virtually any target in weeks. </li></ul>
    23. 23. Portfolio companies – Life Science <ul><li>DiLab develops and markets instruments for automation of measurement & analysis in early and preclinical in-vivo drug discovery. </li></ul><ul><li>A Swedish medtech company which developes a new method to prevent brain damage by cooling of the brain. </li></ul><ul><li>A Medtech company developing a new noninvasive accurate method for the diagnosis of malignant melanoma and other skin cancers. </li></ul><ul><li>Develops novel diagnostic kits within the area of IBD (Inflammatory Bowel Disease). </li></ul>
    24. 24. Our success factors Active ownership Growth in value Analysis <ul><li>Skill and commitment </li></ul><ul><li>Active measures to increase value and enable exits </li></ul><ul><li>Careful selection </li></ul>
    25. 25. Investment process Evaluation of business plan Meeting with the company Preliminary due diligence Proposal for term sheet Additional due diligence Final investment decision Shareholders’ agreement
    26. 26. +46 8 763 79 00 [email_address] Please contact SEB Företagsinvest